share_log

Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target

Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target

奥本海默将 Diamedica Therapeutics 上调至跑赢大盘,宣布目标股价为7美元
Benzinga ·  2023/06/22 07:16

Oppenheimer analyst Francois Brisebois upgrades DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announces $7 price target.

奥本海默分析师弗朗索瓦·布里塞波瓦将Diamedica Therapeutics(纳斯达克股票代码:DMAC)从业绩上调至跑赢大盘,并宣布了7美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发